New Effective Targets

James F. Donohue, MD
Video Categories: Breast Cancer and ESMO

Sunil Verma, MD, MSEd, FRCPC discusses new classes of therapies for HR+ Breast Cancer.

July 17, 2018

Explaining Treatment Regimens to Patients with HR+/HER2–Metastatic Breast Cancer

Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2–metastatic breast cancer regarding how long their treatment will last and how it will impact them.

October 6, 2014

QOL Issues in Polycythemia Vera

Emily Knight presents why quality of life is a big issue in polycythemia vera and how she helps patients in management Supported through funding from Incyte